Altimmune, Inc. (ALT)
ALT Stock Price Chart
Explore Altimmune, Inc. interactive price chart. Choose custom timeframes to analyze ALT price movements and trends.
ALT Company Profile
Discover essential business fundamentals and corporate details for Altimmune, Inc. (ALT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 May 2017
Employees
59.00
Website
https://altimmune.comCEO
Jerome Benedict Durso
Description
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT Financial Timeline
Browse a chronological timeline of Altimmune, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $1.75k.
Earnings released on 13 May 2026
EPS came in at -$0.18 surpassing the estimated -$0.25 by +28.00%.
Earnings released on 5 Mar 2026
EPS came in at -$0.27 falling short of the estimated -$0.25 by -8.00%, while revenue for the quarter reached $26.00k , beating expectations by +4.58k%.
Earnings released on 6 Nov 2025
EPS came in at -$0.21 surpassing the estimated -$0.29 by +27.59%, while revenue for the quarter reached $5.00k , beating expectations by +792.86%.
Earnings released on 12 Aug 2025
EPS came in at -$0.27 surpassing the estimated -$0.32 by +15.62%, while revenue for the quarter reached $5.00k , beating expectations by +249.90%.
Earnings released on 13 May 2025
EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.71%, while revenue for the quarter reached $5.00k , beating expectations by +792.86%.
Earnings released on 27 Feb 2025
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%, while revenue for the quarter reached $5.00k , beating expectations by +400.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $5.00k , beating expectations by +600.28%.
Earnings released on 8 Aug 2024
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%, while revenue for the quarter reached $5.00k , beating expectations by +600.28%.
Earnings released on 9 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.36 by +5.56%, while revenue for the quarter reached $5.00k .
Earnings released on 27 Mar 2024
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $37.00k , beating expectations by +1.63k%.
Earnings released on 7 Nov 2023
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $362.00k , beating expectations by +42.14k%.
Earnings released on 10 Aug 2023
EPS came in at -$0.32 surpassing the estimated -$0.44 by +27.27%, while revenue for the quarter reached $6.00k , beating expectations by +100.00%.
Earnings released on 11 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $21.00k .
Earnings released on 28 Feb 2023
EPS came in at -$0.43 surpassing the estimated -$0.52 by +17.31%, while revenue for the quarter reached $110.00k , beating expectations by +281.19%.
Earnings released on 10 Nov 2022
EPS came in at -$0.48 surpassing the estimated -$0.49 by +2.04%, while revenue for the quarter reached $2.00k , missing expectations by -99.77%.
Earnings released on 11 Aug 2022
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $8.00k , missing expectations by -99.08%.
Earnings released on 12 May 2022
EPS came in at -$0.44 surpassing the estimated -$0.57 by +22.81%, while revenue for the quarter reached $32.00k , missing expectations by -96.90%.
Earnings released on 15 Mar 2022
EPS came in at -$0.49 surpassing the estimated -$0.64 by +23.44%, while revenue for the quarter reached $3.28m , beating expectations by +3.53k%.
Earnings released on 9 Nov 2021
EPS came in at -$0.81 falling short of the estimated -$0.36 by -125.00%, while revenue for the quarter reached $157.56k , beating expectations by +7.75%.
Earnings released on 10 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$0.44 by +9.09%, while revenue for the quarter reached $137.62k , missing expectations by -92.72%.
ALT Stock Performance
Access detailed ALT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
